Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
DOLBY LABORATORIES, INC. (DLB) has a proposed sale of 3,000 shares of Common Stock through Morgan Stanley Smith Barney LLC Executive Financial Services, listed on the NYSE, with an aggregate value of $188,130.00 as of 08/14/2026.
The filing also lists restricted stock of 1,104 shares dated 05/16/2024 and 1,896 shares dated 12/15/2024 from the issuer, and discloses a prior sale of 3,000 Common shares for $164,700.00 on 05/15/2026 by Revankar.
Dolby Laboratories, Inc. officer Ryan Nicholson, VP, CAO and Corporate Controller, sold 1,348 shares of Class A common stock on 2026-08-10 at $62.04 per share in an open market or private transaction. Following the sale, he reported 35,636 shares held directly, including 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories, Inc. insider Ryan H. Nicholson filed to sell common stock through Morgan Stanley Smith Barney LLC. The notice covers 1,348 common shares, with an indicated aggregate value of $83,630.05, to be sold on or after 08/10/2026 on the NYSE. The shares relate to prior restricted stock awards granted in 2020 and 2021. Over the past three months, Nicholson has already sold 357 shares for proceeds of $21,644.91.
Dolby Laboratories, Inc. executive Ryan Nicholson, VP, CAO and Corporate Controller, sold 357 shares of Class A Common Stock on August 4, 2026 at $60.63 per share. After this sale, he holds 36,984 shares, including 19,303 underlying restricted stock units subject to vesting and 385 shares acquired through the Employee Stock Purchase Plan.
Dolby Laboratories SVP, Entertainment John D. Couling exercised employee stock options for 7667 shares of Class A common stock at an exercise price of $45.5000 and, on the same day, sold 783 shares at a weighted average price of $59.0343 and 6884 shares at $60.1075 pursuant to a Rule 10b5-1 trading plan. He continues to hold options for 15334 shares, and his holdings include 55,114 shares underlying restricted stock units that remain subject to vesting conditions.
Dolby Laboratories, Inc. (DLB) insider John Couling filed to sell common stock under a planned transaction. The filing lists 7,667 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $460,003.90, in connection with a stock option exercise
Dolby Laboratories reported total revenue of 304,995 (in thousands) for the quarter ended June 26, 2026, slightly below 315,546 (in thousands) a year earlier, as licensing continued to contribute 93% of revenue. International markets supplied 66% of revenue, with broadcast and mobile remaining the largest licensing segments.
Net income attributable to Dolby declined to 28,602 (in thousands) from 46,071 (in thousands), and diluted EPS was $0.30 versus $0.48. Operating income fell to 34,316 (in thousands), reflecting higher restructuring charges and modestly higher operating expenses. The effective tax rate increased to 33.3% from 16.2%, reducing after‑tax earnings.
Year to date, revenue was 1,047,331 (in thousands), slightly above 1,042,106 (in thousands), while net income attributable to Dolby decreased to 176,844 (in thousands) from 205,686 (in thousands). Dolby ended the period with cash and cash equivalents of 669,394 (in thousands) and long‑term investments of 86,437 (in thousands), after funding 200,001 (in thousands) of share repurchases year to date and paying cash dividends of $0.36 per share in each of the first three fiscal quarters.
Dolby Laboratories, Inc. reported financial results for the third quarter of fiscal 2026, with total revenue of 304,995 (in thousands) versus 315,546 (in thousands) a year earlier. Net income attributable to Dolby was 28,602 (in thousands), or diluted earnings per share of $0.30, compared with $0.48 in the prior-year quarter. Non-GAAP net income was 65,149 (in thousands), or non-GAAP diluted earnings per share of $0.69.
For the fiscal year-to-date, revenue was 1,047,331 (in thousands) and net income attributable to Dolby was 176,844 (in thousands). The board declared a cash dividend of $0.36 per share on Class A and Class B common stock and increased the stock repurchase program by $350 million, bringing remaining authorization to approximately $427 million. Dolby also provided fourth-quarter and full-year fiscal 2026 guidance, including GAAP diluted earnings per share of $0.78–$0.93 for Q4 and $2.62–$2.77 for the full year, and corresponding non-GAAP diluted earnings per share of $1.13–$1.28 and $4.25–$4.40.
Dolby Laboratories, Inc. senior vice president of Entertainment John D. Couling reported an option exercise and related share sale. On July 1, 2026, he exercised employee stock options to acquire 7,667 shares of Class A common stock at $45.50 per share and sold 7,667 shares in open-market transactions at a weighted average price of $53.2013 per share. After these transactions, he directly holds 118,727 shares of Class A common stock, which the filing notes includes 55,114 shares underlying restricted stock units that remain subject to vesting. The derivative holdings section shows 23,001 employee stock options remaining outstanding following the exercise.
DLB submitted a Form 144 notice reporting proposed sale of 7,667 shares of Common Stock via a stock option exercise to occur on 07/01/2026. The filing lists the transaction type as Stock Option Exercise and indicates cash proceeds. The filing also records three recent sales by the same person: 7,666; 7,666; and 4,688 shares on prior dates with corresponding gross proceeds shown.